Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.88 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.88 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TERT | O14746 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442751 | 0.94 | PIN1 (1.00) | PIN1PIN4GSK3AGSK3BALDH1A1 | |
| SCHEMBL18348920 | 0.87 | PIN1 (0.85) | PIN1PIN4GSK3AGSK3BALDH1A1 | |
| SCHEMBL22140316 | 0.81 | PIN1 (0.74) | PIN1PIN4GSK3AGSK3BALDH1A1 | |
| SCHEMBL11453331 | 0.81 | ALDH1A1 (0.77) | PIN1PIN4GSK3AGSK3BALDH1A1 | |
| SCHEMBL11395567 | 0.81 | PIN1 (0.75) | PIN1PIN4ALDH1A1MAPTHTT | |
| SCHEMBL10819259 | 0.80 | PIN1 (0.68) | PIN1PIN4GSK3AGSK3BALDH1A1 | |
| SCHEMBL521934 | 0.78 | PIN1 (0.70) | PIN1PIN4GSK3AGSK3BALDH1A1 | |
| SCHEMBL13148744 | 0.77 | KDM4E (0.62) | PIN1PIN4ALDH1A1TERTMAPT | |
| SCHEMBL522944 | 0.77 | PIN1 (0.68) | PIN1PIN4GSK3AGSK3BALDH1A1 | |
| SCHEMBL523511 | 0.77 | PIN1 (0.68) | PIN1PIN4GSK3AGSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218632-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-07-14 | — | — | US | disclosed |
| US-20180072814-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9796784-B2 | Methods and compositions for the generation and use of conformation-specific antibodies | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160175292-A1 | Antioxidants Having Aromatic Structures Reacting with Superoxide | TOUR JAMES (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150038683-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20140242100-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8802439-B2 | Methods for enhancing infectivity of retroviruses | NATIONAL INSTITUTES OF HEALTH | 2014-08-12 | — | — | US | disclosed |
| US-8771693-B2 | Methods and compositions for the generation and use of conformation-specific antibodies | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2733213-A1 | Kit for producing a retrovirus with enhanced infectivity | Saphire, Andrew C. (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2432885-B1 | METHODS FOR ENHANCING INFECTIVITY OF RETROVIRUSES | SAPHIRE ANDREW C (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20130028900-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120064604-A1 | METHODS FOR ENHANCING INFECTIVITY OF RETROVIRUSES | NATIONAL INSTITUTES OF HEALTH | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218632-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | AR, CDK4, PIN1 | PIN1 3/4885PIN4 531/4885GSK3A 100/4885 |
| US-20160175292-A1 | Antioxidants Having Aromatic Structures Reacting with Superoxide | GPX4, TXN2, MPO | PIN1 3501/4885PIN4 1849/4885GSK3A 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.